Reaches Last Patient Last Visit in Phase 2b Study of VDA-1102 in Actinic Keratosis
Vidac Pharma Holding PLCby Sandra GamzonBusiness news for the stock marketVidac Pharma Holding PLC: Reaches Last Patient Last Visit in Phase 2b Study of VDA-1102 in Actinic KeratosisCompletion of patient follow-up marks a key milestone ahead of data analysisLondon (pta000/15.09.2026/08:40 UTC+2)Vid…